Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:EXOZNASDAQ:IFRXNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$5.87+0.9%$5.39$4.09▼$17.24$125.48M0.81284,623 shs44,679 shsEXOZExozymes$14.00+0.1%$12.05$8.50▼$23.99$117.07MN/A18,691 shs7,350 shsIFRXInflaRx$0.73-59.9%$1.35$0.71▼$2.82$49.04M1.57260,286 shs7.97 million shsQNTMQuantum Biopharma$11.74+1.5%$8.09$2.70▼$18.00$31.77M0.11993,090 shs221,930 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+0.86%+1.38%+4.26%-25.51%-50.80%EXOZExozymes+0.07%-7.59%+24.89%-19.77%+1,399,999,900.00%IFRXInflaRx-59.86%-56.78%-40.12%-47.26%-49.97%QNTMQuantum Biopharma+1.47%-4.55%+69.16%+137.65%+1,173,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.8512 of 5 stars3.41.00.04.73.42.50.0EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx3.0742 of 5 stars3.55.00.00.02.51.70.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25193.87% UpsideEXOZExozymes 0.00N/AN/AN/AIFRXInflaRx 3.00Buy$8.501,063.59% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNTM, EXOZ, ENTA, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$64.46M1.95N/AN/A$5.24 per share1.12EXOZExozymesN/AN/AN/AN/AN/AN/AIFRXInflaRx$129.75K377.96N/AN/A$1.89 per share0.39QNTMQuantum BiopharmaN/AN/AN/AN/A$21.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AIFRXInflaRx-$46.18M-$0.82N/AN/AN/A-33,362.70%-65.98%-56.86%8/14/2025 (Estimated)QNTMQuantum Biopharma-$17.90M-$15.98N/AN/AN/AN/A-84.21%-62.63%8/13/2025 (Estimated)Latest QNTM, EXOZ, ENTA, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A3/20/2025Q4 2024IFRXInflaRx-$0.27-$0.09+$0.18-$0.09$0.13 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47EXOZExozymesN/AN/AN/AIFRXInflaRxN/A5.314.61QNTMQuantum BiopharmaN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%EXOZExozymesN/AIFRXInflaRx42.39%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%EXOZExozymesN/AIFRXInflaRx16.30%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableEXOZExozymes298.37 millionN/AN/AIFRXInflaRx6067.13 million56.19 millionOptionableQNTMQuantum BiopharmaN/A2.71 million1.76 millionN/AQNTM, EXOZ, ENTA, and IFRX HeadlinesRecent News About These CompaniesQuantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28 at 8:00 AM | globenewswire.comQuantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic GrowthMay 21, 2025 | nasdaq.comQuantum BioPharma Partners with BitGo to Securely Store its Crypto Currency AssetsMay 21, 2025 | thestar.comQuantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple SclerosisMay 20, 2025 | globenewswire.comQuantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000May 19, 2025 | globenewswire.comQuantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare ConferenceMay 16, 2025 | globenewswire.comQuantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND SubmissionMay 13, 2025 | nasdaq.comQuantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MSMay 13, 2025 | multiplesclerosisnewstoday.comQuantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple SclerosisMay 12, 2025 | globenewswire.comQuantum BioPharma Ltd. (QNTM) Business Update Conference Call TranscriptMay 6, 2025 | seekingalpha.comQuantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/SpoofingMay 5, 2025 | globenewswire.comQuantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern TimeApril 24, 2025 | globenewswire.comQuantum BioPharma adds Kevin Malone as advisorApril 24, 2025 | uk.investing.comQuantum Group appoints Malone as advisor to Board of DirectorsApril 23, 2025 | markets.businessinsider.comQuantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board AdvisorApril 22, 2025 | globenewswire.comQuantum BioPharma Corporate UpdateApril 18, 2025 | newsfilecorp.comQuantum Group wins reconsideration motion by Dr. Bokhari at CoA for OntarioApril 14, 2025 | markets.businessinsider.comQuantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for OntarioApril 14, 2025 | globenewswire.comQuantum BioPharma’s licensee expands retail reach with AATAC dealApril 12, 2025 | uk.investing.comQuantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto RicoApril 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting WrongSavvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs It Time to Buy the Dip in Novo Nordisk Stock?By Chris Markoch | May 15, 2025View Is It Time to Buy the Dip in Novo Nordisk Stock?Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsBy Jea Yu | April 29, 2025View Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsIs Reddit Stock a Buy, Sell, or Hold After Earnings Release?By Gabriel Osorio-Mazilli | May 5, 2025View Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?QNTM, EXOZ, ENTA, and IFRX Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$5.87 +0.05 (+0.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$5.86 0.00 (-0.09%) As of 05/28/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Exozymes NASDAQ:EXOZ$14.00 +0.01 (+0.07%) As of 05/28/2025 01:10 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.InflaRx NASDAQ:IFRX$0.73 -1.09 (-59.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.44%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Quantum Biopharma NASDAQ:QNTM$11.74 +0.17 (+1.47%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$11.66 -0.09 (-0.72%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
